Eledon Pharmaceuticals Inc (ELDN)

Eledon Pharmaceuticals Inc (ELDN) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $190M; returns 1 day +0.0%, 1 week +8.0%, 1 year -30.1%.

Eledon Pharmaceuticals Inc. (ELDN) is a clinical-stage biotechnology company focused on developing immune-modulating therapies for life-threatening conditions. Their lead product candidate is tegoprubart, an anti-CD40L antibody, which is being investigated for organ transplantation, islet cell transplantation for type 1 diabetes, and amyotrophic lateral sclerosis (ALS).

Groups ELDN belongs to

• Biotechnology
• Clinical Stage
• Clinical Stage Biotech
• Healthcare
• Antibody Therapeutics
• Organ Transplantation
• Immunotherapy
• Biopharmaceutical
• Type 1 Diabetes
• Life Sciences
• Rare Diseases

ELDN financial model: income statement, cash flow and balance sheet